August 14, 2014 Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
August 12, 2014 Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
August 5, 2014 Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
July 31, 2014 Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
July 29, 2014 Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
July 21, 2014 Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
June 30, 2014 Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program
June 25, 2014 Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves Insulin Sensitivity and Lipid Profiles in Study of Pre-Diabetic, Obese Patients
